Daniel S. Levine

Daniel S. Levine is editor of Rare Daily. You can contact him by sending email to editor@globalgenes.org

Making Waves
The U.S. Food and Drug Administration has chosen Wave Life Sciences’ planned phase 2/3 study of suvodirsen, its lead experimental therapy… Continue Reading
FDA Grants Pfizer Priority Review for ATTR Drug
Rare Daily Staff The U.S. Food and Drug Administration granted Priority Review to Pfizer for its application to market tafamidis, its… Continue Reading
Pharma R&D Returns Fall to Lowest Level in Nine Years
Rare Daily Staff Projected returns on investment in pharma research and investment for the top 12 pharmaceutical companies have fallen to… Continue Reading
Report: Cost of Drug Development for Orphan Drugs Less Than for Non-Orphan Drugs
Drug prices have captured the political and public spotlight as a primary target for reining in the soaring cost of healthcare. At the same… Continue Reading
Aspa Therapeutics Forges Gene Therapy for Rare Neurological Condition
Aspa Therapeutics is a subsidiary of Bridge Bio that was created to develop a gene therapy to treat Canavan disease, a progressive and fatal… Continue Reading
EUSA Pharma Acquires Castleman’s Disease Drug from Janssen Science Ireland
Rare Daily Staff EUSA Pharma said it has successfully completed the acquisition of the worldwide rights to the Castleman’s disease drug… Continue Reading
NEJM Study Shows Positive Results of Sanofi’s Drug for Rare Blood Disorder
Rare Daily Staff A study published in The New England Journal of Medicine showed positive results of the phase 3 trial of Cablivi,… Continue Reading

Follow us on Twitter